7239-81-8

Basic information

• Product Name: tris(trimethylsilyl)silicon
• Synonyms: tris(trimethylsilyl)silicon;1H-IMidazo[4,5-c]pyridine-2(3H)-thione
• CAS NO: 7239-81-8
• Molecular Formula: C₆H₅N₃S
• Molecular Weight: 248.66
• Mol File: 7239-81-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: tris(trimethylsilyl)silicon(CAS DataBase Reference)
• NIST Chemistry Reference: tris(trimethylsilyl)silicon(7239-81-8)
• EPA Substance Registry System: tris(trimethylsilyl)silicon(7239-81-8)

Safety Data

• Hazardous Substances Data: 7239-81-8(Hazardous Substances Data)

Usage

General Description

Tris(trimethylsilyl)silicon, also known as TTMSS, is a chemical compound with the molecular formula (CH3)3Si3Si(CH3)3. It is an organosilicon compound that is used as a versatile reagent in organic synthesis. TTMSS is commonly employed as a silylating agent and as a source of silicon in various chemical reactions. Its reactivity arises from the three trimethylsilyl (TMS) groups attached to a central silicon atom, which allows TTMSS to donate or accept silicon in a variety of chemical transformations. TTMSS is a colorless, flammable liquid that is handled and stored under inert gas atmospheres to prevent reaction with air and moisture. It is an important reagent in the field of organosilicon chemistry and finds applications in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals.

InChI:InChI=1/4C9H27Si4.4ClH.4Sn/c4*1-11(2,3)10(12(4,5)6)13(7,8)9;;;;;;;;/h4*1-9H3;4*1H;;;;/q;;;;;;;;4*+1/p-4/r4C9H27Si4.4ClSn/c4*1-11(2,3)10(12(4,5)6)13(7,8)9;4*1-2/h4*1-9H3;;;;

Upstream product

• 1681-37-4 4-amino-3-nitropyridine 
• 54-96-6 3,4-diaminopyridine 
• 272-97-9 Imidazo<4,5-c>pyridin 
• 140-89-6 potassium ethyl xanthogenate 
• 13037-22-4 methyl (N-(4-methylphenyl))dithiocarbamate 
• 75-15-0 carbon disulfide 

Downstream Products

• 7397-69-5 2-methylthioimidazo<4,5-c>pyridine 
• 135903-94-5 2-[(2-Phenylethyl)thio]-1H-imidazo[4,5-c]pyridine 
• 135903-92-3 2-[[(phenyl)methyl]thio]-1H-imidazo[4,5-c]pyridine 
• 135903-87-6 2-[[(3,4-Dichlorophenyl)methyl]thio]-1H-imidazo[4,5-c]pyridine 
• 134217-26-8 2-[[(3-methoxyphenyl)methyl]thio]-1H-imidazo[4,5-c]pyridine 

Relevant articles and documents

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

FUSED HETEROCYCLIC COMPOUNDS

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Production of certain 2-phenylalkylthio-and 2-phenylalkylsulfinyl imidazo[4,]pyridines

This invention relates to the process for the preparation of certain 2-phenylalkylthio- and phenylalkylsulfinyl-imidazo[4,5-c]pyridines useful for the treatment of osteoporosis.